CLINICAL TRIAL

KRT-232 for Leukemia, Myeloid, Acute

Recruiting · 18+ · All Sexes · Anderlecht, Belgium

This study is evaluating whether a combination of two drugs may help treat AML.

See full description

About the trial for Leukemia, Myeloid, Acute

Eligible Conditions
Leukemia · Myeloproliferative Disorders · Leukemia, Myeloid, Acute · Leukemia, Myeloid · Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN) · Relapsed or Refractory Acute Myeloid Leukemia (AML)

Treatment Groups

This trial involves 6 different treatments. KRT-232 is the primary treatment being studied. Participants will be divided into 6 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.

Experimental Group 1
KRT-232
DRUG
Experimental Group 2
Cytarabine
DRUG
+
KRT-232
DRUG
Experimental Group 3
KRT-232
DRUG
+
Decitabine
DRUG
Show More

About The Treatment

Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cytarabine
FDA approved
Decitabine
FDA approved

Eligibility

This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Leukemia, Myeloid, Acute or one of the other 5 conditions listed above. There are 5 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Part B:Patients with relapsed or refractory AML secondary to MPN (myelofibrosis [MF], polycythemia vera [PV], or essential thrombocythemia [ET]); patients may have been treated with ≥1 prior lines of therapy for their AML secondary to MPN.
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 2 years after last patient enrolled
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 2 years after last patient enrolled.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether KRT-232 will improve 2 primary outcomes and 2 secondary outcomes in patients with Leukemia, Myeloid, Acute. Measurement will happen over the course of 12 weeks.

Part B: To determine the rates of complete remission (CR), CR with partial hematological improvement (CRh) and CR with incomplete hematologic recovery (CRi)
12 WEEKS
Proportion of patients achieving complete remission (CR), complete remission with partial hematological improvement (CRh), and CR with incomplete hematologic recovery (CRi) as determined by Modified 2017 European LeukemiaNet (ELN) response criteria
Part A: To determine the rates of complete remission (CR) and complete remission with partial hematological improvement (CRh)
12 WEEKS
Proportion of patients achieving complete remission (CR) or complete remission with partial hematological improvement (CRh) as determined by Modified 2017 European LeukemiaNet (ELN) response criteria
Part A: To determine KRT-232 recommended phase 2 dose (RP2D)
28 DAYS
Number of dose-limiting toxicities (DLTs) of KRT-232 in combination with cytarabine or decitabine
Part B: To determine the RP2D of KRT-232
2 YEARS AFTER LAST PATIENT ENROLLED
The safety review committee (SRC) will determine the RP2D based on safety and tolerability data obtained from each arm

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is leukemia, myeloid, acute?

Leukemia, myeloid, acute typically begins in children who are between the ages of 4-19. On average, the leukemia, myeloid, acute diagnosis occurs in a patient when they are between the ages of 4-20.

Anonymous Patient Answer

What are common treatments for leukemia, myeloid, acute?

Almost all anticancer therapies used today are for leukemia, myeloid, acute. The average lifespans for patients with leukemia and myeloid, acute continue to increase. Patients with early stage leukemia, but not those with late stage, are eligible for intensive chemotherapy as it is very effective (http://www.medscape.org/pdf/courses/oncology_treatment.pdf). In order to keep a leukemia-free lifestyle the patient usually must meet the chemotherapy drug treatment outlined in the cancer treatment guideline's given to them in advance by a physician. There are several options to keep the disease from resurfacing again at a different site.

Anonymous Patient Answer

What causes leukemia, myeloid, acute?

A high percentage of childhood cancer survivors have some form of leukemic disorders. This suggests that exposures to genetic, environmental, and occupational predisactives may play an important role in the development of leukemia and lymphoid disorders in former cancer patients.

Anonymous Patient Answer

Can leukemia, myeloid, acute be cured?

As a small percentage of patients with acute leukemia, asymptomatic chronic monocytic leukemia, and chronic myelogenous leukemia can have spontaneous remission of their leukemic disease with the disappearance of leukemia-related symptoms, physicians should be aware of this potential complication of leukemic disease.

Anonymous Patient Answer

What are the signs of leukemia, myeloid, acute?

The common signs of leukemia, myeloid, acute include easy bruising, fatigue, low number of white blood cells, enlarged spleen, enlarged liver, and itchiness, among others. The signs of leukemia, myeloid, acute have no effect on the quality of life of the patients. Therefore, patients are not advised to limit their activities on account of the signs of leukemia, myeloid, acute as it can have a significant impact on their quality of life and can lead to further adverse consequences. The signs are all non-specific, and are also present in chronic diseases. It is only on the basis of the symptoms and signs that diagnosis can be made.

Anonymous Patient Answer

How many people get leukemia, myeloid, acute a year in the United States?

The prevalence of CLL is 9.5/100,000 per year. The prevalence of MAL is 0.36/100,000 per year, while the incidence is 0.01/100,000 per year. For AML the prevalence is 4.9/100,000 per year while its incidence is 0.01/100,000 per year. For CML the prevalence is 7.8/100,000 and the incidence is 1.9/100,000 per year. Because CLL and MM are relatively rare, diagnosis and reporting of these conditions may be biased towards the incidence in more developed countries.

Anonymous Patient Answer

What is the latest research for leukemia, myeloid, acute?

A review of a set of leukemia research papers was published by the [British Society of Haematology Leukemia, myeloid, acute review group]. The following research papers were cited in the review, which also included 3 papers with no clear citations, all of these articles are published in scientific, peer-reviewed journals and are thus considered to constitute the latest scientific research (with the exception of the case of paper 4, which was published in a journal of Chinese Medicine).

Anonymous Patient Answer

What are the chances of developing leukemia, myeloid, acute?

It is not possible to predict how much and how fast a person will develop [leukemia, myeloid, acute] and it is also possible to know whether your bone marrow is at risk. What will happen to you when you go to the doctor to be tested? The best thing to do is to make sure your doctor is aware of your risks, so they can recommend the best and most right course of action.

Anonymous Patient Answer

Who should consider clinical trials for leukemia, myeloid, acute?

Although there is little evidence that any given regimen is superior to other regimens, a number of well-designed studies, including those that compare new agents to existing agents, may also be relevant. However, it is important that investigators enroll only patients for whom their initial therapy is considered inappropriate, since there is virtually no evidence that a better-than-usual outcome will be observed in a trial that enrolls patients who are initially treated appropriately.

Anonymous Patient Answer

Is krt-232 typically used in combination with any other treatments?

Recent findings provides a comprehensive overview of the clinical use of Krt-232 in HCC. The current knowledge of a low toxicity profile and minimal evidence for a therapeutic role of Krt-232 in HCC suggests this radionuclide as a viable agent for future investigation in HCC treatment.

Anonymous Patient Answer

How quickly does leukemia, myeloid, acute spread?

For the group of patients who were diagnosed with the AML/MVA disease, the percentage and risk of progression of that disease can be significantly reduced by administering chemotherapy from 7 through 12 years as compared to receiving no treatment or a prophylactic regimen. Recent findings suggest one or more of the reasons for disease progression and shorter life expectancy of AML patients. Recent findings can help guide the treatment of AML patients.

Anonymous Patient Answer

What is the survival rate for leukemia, myeloid, acute?

Because survival may differ depending on the age at diagnosis, and the length of exposure to therapy (especially if the initial therapy is less complete), we cannot necessarily equate survival rates observed in clinical trials to patients outside the trial population. It's true that chemotherapy tends to cure patients that come in at an older age or at their first treatment, but their chances of being treated to completion are higher.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Leukemia, Myeloid, Acute by sharing your contact details with the study coordinator.